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Abstract: 
It is known that SPARC gates VEGF-A signal transduction towards KDR, the primary 
angiogenic VEGF receptor. We sought to determine whether inhibition of SPARC activity using 
anti-SPARC peptide could inhibit laser-induced CNV by promoting binding of VEGF-A to FLT-
1. We created anti-SPARC L-peptide and retro-inverso anti-SPARC D-peptide. Anti-SPARC 
peptides or PBS were injected intravitreally one day before or after laser induction. Intravitreal 
injection of anti-SPARC L-peptide one day before laser induction promotes Flt-1 
phosphorylation and inhibited laser-induced CNV and anti-SPARC D-peptide had no effect. 
Injection one day after laser injury did not affect size of laser-induced CNV. Inhibition of 
SPARC activity could be complementary to existing anti–CNV therapy. 
 
Article: 
INTRODUCTION 
Neovascularization, the abnormal growth of new blood vessels, plays an important role in many 
diseases, including cancer and blindness (Bellner, Vitto, Patil, Dunn, Regan & Laniado-
Schwartzman, 2008, Epstein, Stulting, Hendricks & Harris, 1987, Folkman, 1990). In patients 
with age-related macular degeneration (AMD) choroidal neovascularization (CNV) is a principal 
cause of blindness (Smith, Assink, Klein, Mitchell, Klaver, Klein, Hofman, Jensen, Wang & de 
Jong, 2001). CNV grows from the choroid into the subretinal space. These blood vessels may 
bleed into the subretinal space resulting in edema and tissue damage. Vascular endothelial 
growth factor (VEGF) has been found to be a potent stimulator of CNV (Amin, Puklin & Frank, 
1994, Ng & Adamis, 2005). FLT-1 (also referred as VEGF receptor-1) and KDR (also referred 
as VEGF receptor-2) are the principal VEGF receptors and are critically involved in 
neovascularization and angiogenesis (de Vries, Escobedo, Ueno, Houck, Ferrara & Williams, 
1992, Matsumoto, Bohman, Dixelius, Berge, Dimberg, Magnusson, Wang, Wikner, Qi, 
Wernstedt, Wu, Bruheim, Mugishima, Mukhopadhyay, Spurkland & Claesson-Welsh, 2005, 
Shibuya, 1995, Shibuya, 2006, Shibuya & Claesson-Welsh, 2006). Generally, activation of KDR 
by VEGF promotes angiogenesis. On the other hand, FLT-1 signaling has been reported to both 
promote (Carmeliet, Moons, Luttun, Vincenti, Compernolle, De Mol, Wu, Bono, Devy, Beck, 
Scholz, Acker, DiPalma, Dewerchin, Noel, Stalmans, Barra, Blacher, Vandendriessche, Ponten, 
Eriksson, Plate, Foidart, Schaper, Charnock-Jones, Hicklin, Herbert, Collen & Persico, 2001, 
Hiratsuka, Maru, Okada, Seiki, Noda & Shibuya, 2001) and suppress angiogenesis (Bussolati, 
Dunk, Grohman, Kontos, Mason & Ahmed, 2001, Kearney, Ambler, Monaco, Johnson, 
Rapoport & Bautch, 2002), depending on the tissue and context. In addition, due to alternative 
splicing, the FLT-1 gene produces membrane-bound FLT-1 and soluble FLT-1 isoforms. Soluble 
FLT-1 has a partial extracellular domain of membrane FLT-1 and a unique C-terminal peptide. 
Soluble FLT-1 binds VEGF-A as an extracellular antagonist and blocks its signaling. It is known 
that soluble FLT-1 is vital to corneal avascularity (Ambati, Nozaki, Singh, Takeda, Jani, Suthar, 
Albuquerque, Richter, Sakurai, Newcomb, Kleinman, Caldwell, Lin, Ogura, Orecchia, 
Samuelson, Agnew, St Leger, Green, Mahasreshti, Curiel, Kwan, Marsh, Ikeda, Leiper, 
Collinson, Bogdanovich, Khurana, Shibuya, Baldwin, Ferrara, Gerber, De Falco, Witta, Baffi, 
Raisler & Ambati, 2006). While VEGF is critical to angiogenesis, VEGF overexpression alone 
does not induce CNV in mice (Oshima, Oshima, Nambu, Kachi, Hackett, Melia, Kaleko, 
Connelly, Esumi, Zack & Campochiaro, 2004). This indicates other cellular or extracellular 
components may play key roles in the development of CNV. 
 
In this study, we focused on the role of SPARC (secreted protein, acidic and rich in cysteine; 
also known as BM-40 and osteonectin) in laser-induced CNV, a well-established model for age-
related macular degeneration. SPARC belongs to the matricellular family that mediates cell-
matrix interactions, which affect biological functions including proliferation, survival, adhesion 
and migration (Bornstein & Sage, 2002). SPARC binds to VEGF and inhibits tyrosine 
phosphorylation of FLT-1 but not KDR (Kupprion, Motamed & Sage, 1998). Nozaki et al. 
demonstrated reduced SPARC temporarily after laser injury in the choroid, creating a window of 
permissibility for VEGF binding to FLT-1. FLT-1 activation inhibits signal transduction of KDR 
through SHP-1 and can decrease laser-induced CNV volume (Nozaki, Sakurai, Raisler, Baffi, 
Witta, Ogura, Brekken, Sage, Ambati & Ambati, 2006). Based on these earlier studies we 
hypothesized inhibition of SPARC activity could reduce or prevent laser-induced CNV. Based 
on this hypothesis we created anti-SPARC peptides to bind SPARC by phage screening and 
examined the effect of anti-SPARC peptides on a laser-induced CNV model. 
 
METHODS 
Phage screening for anti-SPARC peptide 
The Ph.D.™ Phage Display Peptide Library Kit (New England Biolabs, Ipswich, USA) was used 
for in vitro biopanning procedures. This ligand screening system is based on a library of random 
peptide 7-mers fused to a minor coat protein, pIII, of the filamentous coliphage M13. Phage 
selection in vitro was performed according to the manufacture’s protocol. SPARC recombinant 
proteins were coated on 96-well plates in 0.1M NaHCO3 coating buffer and incubated overnight 
at 4°C. The next day the plates were washed with 0.1% Tween-20 in TBS (TBST), followed by 
blocking in 3%BSA for 1 hour. In the first round of biopanning, 2 × 1011 phage (100 equivalents 
of original library) were added to each well with 0.1% bovine serum albumin (BSA) and 
incubated for 1 hour at room temperature. The plates were then washed ten times with TBST. 
After washing, 100µl of 0.2 M Glycine-HCl (pH 2.2) and 1 mg/ml BSA were added to the wells 
to elute recombinant protein bound phage. One microliter of eluted phage was tittered on 
LB/IPTG/Xgal plates and blue plaques were counted and phage titer was determined. The 
remaining phage was amplified using ER2738 E. Coli in LB-Tet according to the manufacture’s 
instructions. For the following steps 2 × 1011 pfu plaques were use. We performed 4 cycles of 
binding and amplification on the previously eluted and amplified phage to enrich the pool in 
favor of binding sequences. 
 
Surface Plasmon Resonance 
Interaction between anti-SPARC L- or D-peptide and SPARC was determined by Biacore 2000 
(GE Healthcare/Biacore, Uppsala, Sweden). SPARC from PYS-2 cell (sigma) was immobilized 
using standard amine-coupling chemistry to a density of 2100 resonance units (RU). As a 
control, we also immobilized 2100 RU carbonic anhydrase. The peptides were tested in duplicate 
in a two-fold dilution series for binding to the protein surfaces. Fitting the responses to a simple 
binding isotherm yielded the affinities. 
 
Intravitreal peptide injection 
Wild-type C57/BL6 mice were purchased from Jackson Laboratory. Mice (6 to 8 weeks old) 
were anesthetized by intraperitoneal injection of Ketaset® (50mg/kg; Wyeth, Fort Dodge, USA) 
and xylazine (Tranqui Ved, 10mg/kg; VEDCO, St. Joseph, USA). Anti-SPARC L-peptide (20ng 
or 2µg), anti-SPARC D-peptide (20ng or 2µg), or PBS, as a control, was injected into the 
vitreous cavity in a total volume of 1µl with 33-gauge micro syringe (Hamilton Company, Reno, 
USA). 
 
Laser induced choroidal neovascularization 
Laser photocoagulation (532nm, 100mV, 100ms, 50µm; NIDEK MC-4000) was performed on 
both eyes (2 to 5 spots per eye) as described (Sakurai, Anand, Ambati, van Rooijen & Ambati, 
2003, Sakurai, Taguchi, Anand, Ambati, Gragoudas, Miller, Adamis & Ambati, 2003). After 
enucleating the eyes, sclera/choroid/RPE complex were fixed in 4% paraformaldehyde for 2 
hours at 4 °C. After blocking in 5% FBS/PBS with 0.02% tritonX-100 and 2mM MgCl2, 
samples were stained with 5µg/ml Alexa488 conjugated isolectin GS-IB4 (Invitrogen 
Corporation, Carlsbad, USA) overnight. After washing the samples were flat mounted on glass 
slides. CNV volume was measured by scanning laser confocal microscopy (Olympus America 
Inc., Center Valley, USA). 
 
Immunoprecipitation and Western blot 
After euthanizing the mice, RPE/choroid complex was separated from sclera under a 
stereomicroscope and placed in 200 µl of RIPA buffer (Sigma-Aldrich, St. Louis, USA) 
containing protease inhibitor cocktail (Roche Diagnostics Corporation, Indianapolis, USA) and 
Halt™ phosphatase inhibitor (Fisher Scientific, Pittsburg, USA). After homogenization with a 
sonic dismembrator (Fisher Scientific, Pittsburg, USA), 150 µl samples were subjected to 
immunoprecipitation for FLT-1 or KDR. For immunoprecipitation we used protein G or A 
coated magnetic beads (Invitrogen Corporation, Carlsbad, USA) and mouse anti-FLT-1 antibody 
or rabbit anti-KDR antibody (Abcam Inc., Cambridge, USA) following manufacture’s 
instructions. The proteins were eluted with Laemmli buffer for 10 minutes at 70°C and resolved 
by SDS-PAGE (8%) under reducing conditions. The protein was transferred to a nitrocellulose 
membrane and incubated for 1 hour with blocking buffer (3%BSA and 0.05% Tween20 in TBS) 
then incubated with anti-phospho-FLT-1(Tyr1213) antibody (1:1000, Millipore, Billerica, USA) 
or anti-tyrosine phosphorylation antibody in blocking buffer for 1 hour at room temperature. The 
membrane was washed once in TBST (0.05% Tween20/TBS) and twice in TBS. Finally, the 
membrane was incubated with the appropriate secondary HRP-linked antibody in blocking 
buffer for 30 minutes at room temperature. After washing once with TBST and thrice with TBS, 
the bands were illuminated by an ECL-PLUS Western Blot detection kit (Amersham 
Biosciences, Pittsburg, USA) and detected by FOTO/Analyst Electronic Imaging Systems 
(Fotodyne Inc., Hartland, USA). 
 
Statistics 
Data are shown as mean ± s.e.m or s.d. P values were calculated using Student’s t-test 
 
RESULTS 
Generation of anti-SPARC peptide 
SPARC is expressed in retinal pigment epithelium (RPE) (Hiscott, Hagan, Heathcote, Sheridan, 
Groenewald, Grierson, Wong & Paraoan, 2002). In addition, we detected SPARC in the cornea, 
lens and retina by immunohistochemistry, although the signal intensities less than RPE (data not 
shown). Laser-induced CNV occurs from the choroid to the retina through the RPE. The RPE is 
thought to play a key role in early and late stage AMD (Schmitz-Valckenberg, Fleckenstein, 
Scholl & Holz, 2009). We had previously determined the probable mode of VEGF-SPARC 
binding via computational molecular docking (Chandrasekaran, Ambati, Ambati & Taylor, 
2007) as well as the relevance of that interaction in gating VEGF angiogenic vs. anti-angiogenic 
effects in a laser-induced CNV model (Nozaki et al., 2006). We therefore hypothesized that 
inhibiting SPARC binding of VEGF would inhibit laser-induced CNV. 
 
To inhibit SPARC activity we employed a small peptide, as we hypothesized small molecules 
would enter the RPE more efficiently and induce less inflammation than antibodies. In addition 
we thought a small peptide would limit only SPARC activity to VEGF effectively. To create the 
peptide blocking SPARC activity we performed phage-screening against SPARC and obtained 
the L-peptide sequence SMPTYNK. There were two small regions of VEGF predicted to have 
significant protein-protein interactions with SPARC (one around residue 200, and another around 
260–270; amino acid number according to Genbank file AAH65522) (Chandrasekaran et al., 
2007). We compared L-peptide SMPTYNK with these regions of VEGF and found two possible 
matches (Fig.1). Results from X-ray crystallographic analysis and mutagenesis studies concluded 
FMDVYQR is a helix near the binding site of VEGF to FLT-1 and KDR (Keyt, Berleau, 
Nguyen, Chen, Heinsohn, Vandlen & Ferrara, 1996, Keyt, Nguyen, Berleau, Duarte, Park, Chen 
& Ferrara, 1996, Wiesmann, Fuh, Christinger, Eigenbrot, Wells & de Vos, 1997). From the 3-D 
docking model of VEGF-SPARC binding (Chandrasekaran et al., 2007) Met (M) and Tyr (Y) 
residues project on the same side of the helix forming an MXXY motif, a feature of SMPTYNK. 
We believe this part of VEGF-A binds to SPARC and inhibits SPARC activity. Based on these 
considerations we selected L-KFMDVYNR as anti-SPARC L-peptide. In addition to anti-
SPARC L-peptide, we synthesized anti-SPARC D-peptide (retro-inverso peptide, 
DRNYVDMFK), sequenced based on anti-SPARC L-peptide. To confirm if anti-SPARC L-
peptide and D-peptide bind to SPARC we measured the interaction by surface plasmon 
resonance (SPR; Table). We found the interaction between SPARC and anti-SPARC L-peptide 
or D-peptide exists although the interactions were weak. 
 
Anti-SPARC L-peptide injection before laser photocoagulation inhibits laser CNV volume 
To determine if anti-SPARC peptide decreases laser CNV volume in mice we injected anti-
SPARC L-peptide or D-peptide at 20ng and 2µg into the intravitreous cavity. One day after the 
injections we performed 2~5 spots of laser photocoagulation in each eye. After 10 days the 
volumes of laser CNV were measured by confocal microscopy. Figure 2 represents the laser 
induced CNV of PBS (a, b), anti-SPARC L-peptide 20ng(c), 2µg (d), and anti-SPARC D-peptide 
20ng (e), and 2µg (f) injections. The anti-SPARC L-peptide injections decreased laser CNV 
volume in a dose-dependent manner compared with PBS injections, however anti-SPARC D-
peptide did not affect the laser induced CNV volume (Fig.2 (g)). The sample number of each 
group was 10–15 laser-CNV spots. 
 
Figure 1: Potential matches of phage display derived L-peptide SMPTYNK to the VEGF protein 
sequence 
 
 
Underlined residues in VEGF are predicted to be sites of interaction with SPARC (Tables 1 and the reference (Chandrasekaran et al., 2007)) by 
H-bonding or predicted hydrophobic interactions (e.g. FM near N-terminus shown). Exact matches are shown in bold, similarities in italics. Note 
that NK in the peptide is functionally similar to QR in VEGF. The partial VEGF-A sequence shown is numbered according to Genbank file 
AAH65522. 
 
 
Table 1: Interaction between anti-SPARC peptides and SPARC protein measured by surface 
plasmon resonance. 
 Dissociation Constant (KD) 
Anti-SPARC L-peptide 2.0 (mM) 
Anti-SPARC D-peptide 1.6 (mM) 
 
 
Figure 2: Anti-SPARC L-peptide injection before laser inhibits CNV 
 
One day before laser injury, PBS, anti-SPARC L-peptide or D-peptide was injected into the intravitreal cavity. Representative fluorescence 
images are shown (a-f). PBS injection as a control (a, b). Anti-SPARC L-peptide injection, 20ng(c) and 2μg (d). Anti-SPARC L-peptide 
injection, 20ng(e) and 2µg(f). Scale bar: 200µm. Anti-SPARC L-peptide(g) reduced laser CNV volume, while anti-SPARC D-peptide showed no 
reduction compared with PBS,. P: risk factor by student t-test. *: p<0.01, **p<0.001. Error bar: s.e.m. 
Anti-SPARC L-peptide injections after laser photocoagulation do not affect laser CNV volume 
We injected anti-SPARC L- or D- peptide at 20ng or 2µg after one day of laser 
photocoagulation. After 10 days the volumes of laser CNV were measured (Fig.3). Unlike anti-
SPARC L-peptide injection before laser photocoagulation, we could not detect a significant 
effect. The sample number of each group was 10–15 laser-CNV spots. 
 
Figure 3: Anti-SPARC peptide injection after laser injury does not affect CNV 
 
One day after laser injury, PBS, anti-SPARC L-peptide and D-peptide were injected intravitreally. Significant differences were not found. Error 
bar: s.e.m. 
  
Anti-SPARC L-peptide increased phosphorylation of FLT-1 and decreased phosphorylation of 
KDR after one day of laser photocoagulation in vivo 
Because it was reported that SPARC sequesters phosphorylation of FLT-1 by VEGF (Kupprion 
et al., 1998), we investigated whether anti-SPARC peptides would decrease SPARC activity in 
RPE/Choroid and eventually decrease phosphorylation of FLT-1. One day after anti-SPARC L-
peptide, D-peptide or PBS injection we performed laser photocoagulation. One to two days later 
RPE/Choroid was carefully dissected from sclera and we examined phosphorylation of FLT-1 
and KDR by western blot (Fig.4). Western blot showed anti-SPARC L-peptide increased 
phosphorylation of FLT-1 after one day of laser photocoagulation compared with PBS or anti-
SPARC D-peptide injection. Two days after laser photocoagulation there were no significant 
differences in phosphorylation of FLT-1. Conversely, phosphorylation of KDR was decreased 
one day after but not two days after laser photocoagulation. 
 
 
 
Figure 4: FLT phosphorylation is increased, but KDR phosphorylation is decreased by anti-
SPARC L-peptide 
 
PBS, anti-SPARC L-peptide or D-peptide were injected to the intravitreous cavity one day before laser injury. One or two days after laser 
photocoagulation, the RPE/choroid was separated from sclera and immunoprecipitation for FLT-1 or KDR and western blot for phosphorylation 
of each protein were performed. (a) FLT-1, (b) KDR. Each figure is representation of three individual experiments. As a control, FLT-1 or KDR 
was examined in the same sample. Densitometric ratio of phosphoFLT-1 to FLT and phosphoKDR to KDR are shown as PBS treated one is 1.0. 
Error is s.d. P: risk factor by student t-test. 
 
DISCUSSION 
VEGF, as a potent inducer of CNV, has been studied and its inhibition by anti-VEGF antibody 
(ranibizumab) has shown improvement of AMD patients’ vision (Chang, Bressler, Fine, Dolan, 
Ward & Klesert, 2007) (Rosenfeld, Brown, Heier, Boyer, Kaiser, Chung & Kim, 2006). Despite 
this discovery, its application has been limited to advanced stages. We believe treatment at 
earlier stages will be necessary to decrease CNV growth or prevent CNV. In addition, clinical 
trials of pegaptanib in AMD patients showed an inverse therapeutic dose response (Gragoudas, 
Adamis, Cunningham, Feinsod & Guyer, 2004). This indicates over-inhibition of VEGF may 
lead to an adverse effect and we hypothesized that the treatment of other targets related to VEGF 
may be helpful for AMD patients. 
 
In addition to VEGF regulation, several other growth factors are affected by SPARC. For 
example, the stimulation of platelet-derived growth factor induced proliferation of human arterial 
vascular smooth muscle is inhibited in the presence of SPARC (Motamed, Funk, Koyama, Ross, 
Raines & Sage, 2002). Transforming growth factor β is also regulated by SPARC (Francki, 
McClure, Brekken, Motamed, Murri, Wang & Sage, 2004). 
 
In this study we focused on SPARC activity as it relates to VEGF. We designed a small peptide 
to inhibit SPARC by phage-screening and previous computational analysis predictions 
(Chandrasekaran et al., 2007). Intravitreal injection of L-anti-SPARC peptide one day before 
laser photocoagulation prevented laser-induced CNV growth. However, we could not find a 
significant difference in laser induced CNV when we injected anti-SPARC peptide after laser 
injury. This may be due to two reasons. (1) Previous studies reported that one day after laser 
photocoagulation SPARC decreased in RPE/choroid temporarily, but recovered the next day 
(Nozaki et al., 2006). Hence, injection of anti-SPARC L-peptide after laser injury may not have a 
target as SPARC had already declined. (2) This may indicate SPARC regulation is operative in 
the initial phases of laser injury and determines the fate of cells in CNV through FLT-1 and KDR 
signaling. This concept is supported by western blot analysis of phosphorylation of FLT-1 and 
KDR (Fig 4). In eyes injected with anti-SPARC L-peptide one day before laser injury, 
phosphorylation of FLT-1 increased. Conversely, KDR phosphorylation decreased one day after 
laser photocoagulation. We could not detect differences in phosphorylation of FLT-1 and KDR 
in eyes treated two days after laser photocoagulation. Alternatively, it is possible that SPARC 
function may change in response to injury (Arnold & Brekken, 2009). 
 
Although surface plasmon resonance showed low interaction between SPARC and anti-SPARC 
L-peptide, anti-SPARC L-peptide injection one day before laser photocoagulation reduced laser-
induced CNV volume. It is possible that our dose of anti-SPARC L-peptide may overcome low 
binding affinity, further underlining the importance of SPARC at the initial stages of laser-
induced CNV. 
 
We successfully prevented laser-induced CNV using anti-SPARC L-peptide, but anti-SPARC D-
peptide, which interacts with SPARC as much as anti-SPARC L-peptide did not inhibit CNV 
compared with PBS injection one day before or after laser photocoagulation. It is unclear why 
the D-peptide did not exert an inhibitory effect; one possibility is that there may be L-peptide 
specific transporters which enable transport of intravitreal peptides across the retina to sites of 
injury. Alternatively, there may be subtle steric interference points in the in vivo extracellular 
matrix blocking the anti-SPARC D-peptide activity. Figure 4 shows that anti-SPARC L-peptide, 
but not anti-SPARC D-peptide, promoted phosphorylation of FLT-1 and decreased 
phosphorylation of KDR. This suggests that anti-SPARC D-peptide may bind to SPARC but not 
inhibit SPARC-VEGF interactions in vivo. 
 
The clinical relevance of finding anti-SPARC intervention to be most effective immediately prior 
to laser-injury in a murine model will depend on progress in assessing SPARC levels in macular 
degeneration patients. Patients with normal or above-normal SPARC levels may benefit from a 
combination of anti-SPARC plus anti-VEGF therapy. 
 
In summary, we have shown that inhibition of SPARC by anti-SPARC L-peptide prior to laser 
photocoagulation reduces the volume of laser-induced CNV and that this is associated with 
increased phosphorylation of FLT-1 and decreased phosphorylation of KDR. Our results also 
confirm that SPARC plays a key role in the initial stages of laser-induced CNV. This may lay the 
foundation for anti-SPARC therapy to complement existing treatments for AMD. 
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